Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

NCT03920267 ↗

Phase 2 Completed 261 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).

Timeline

Start: 2019-03-26
Primary completion: 2025-03-21
Completion: 2025-03-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	—	—

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications